Excedrin Extra Strength OTC indication for migraine pain supported by studies -- Bristol.
This article was originally published in The Tan Sheet
Executive Summary
EXCEDRIN EXTRA STRENGTH OTC INDICATION FOR MIGRAINE PAIN is supported by three clinical trials involving subjects with migraine, according to Bristol-Myers Squibb. Results of the trials, which include comparisons of Excedrin Extra Strength to placebo and to prescription migraine drugs, will be presented by the company at the July 15 joint meeting of FDA's Nonprescription Drugs and Arthritis Advisory Committees ("The Tan Sheet" June 2, p. 3). Representatives from the agency's Peripheral & Central Nervous System Advisory Committee also will attend.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning